Back to top

Palvella submits first rolling new drug application to FDA for Qtorin

Palvella Therapeutics (PVLA) announced that the company has submitted the first module of its rolling new drug application, or NDA, to the FDA seek...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Palvella Therapeutics, Inc. (PVLA)